Popular Terms and Pages:

Cancer Clinical Trials

Clinical trials are research studies involving people that help investigators find new ways to prevent, detect, diagnose or treat cancer and other diseases. All of today’s successful treatments for cancer are based on results of past clinical trials. 

At Redeemer Health in partnership with MD Anderson Cancer Center at Cooper, our team of physicians, nurses and other cancer specialists work together to bring the most innovative clinical trials to our patients. 

Through these clinical trials, patients have access to treatment options that may not be available elsewhere.  

For more information on clinical research trials, please contact Nadine Varney, RN, BS, OCN, CNMT, at nvarney@holyredeemer.com or 215-544-5832.

A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events 
NCT04242095

 

S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
NCT04871542

 

S1904: Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
NCT04496739
 

A221803: Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
NCT04989504  

PER 19-04: A Prospective, Multi-Center, Randomized, Double-Arm Trial to Determine the Impact of the SELENE System on Positive Margin Rates in Breast Conservation Surgery
NCT05113927

 

RT Outcomes: Radiation Therapy Outcomes for Breast Cancer: A Clinical Trial Gathering Prospective Data on Side Effects and Treatment Efficacy – Hospital Registry 

GLSI-21-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/new Peptide GLSI-100 (GP2 + M-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
NCT05232916